-
AstraZeneca Launches Phase I Trial for siRNA Therapy in Collaboration with Silence Therapeutics
•
AstraZeneca (AZ; NASDAQ: AZN) has commenced a Phase I trial for a short interfering RNA (siRNA) therapy targeting an undisclosed disease, marking the first clinical candidate to emerge from its 2020 collaboration with UK-based Silence Therapeutics (NASDAQ: SLN). This partnership aims to develop up to ten siRNA therapeutics across cardiovascular,…
-
b-ONE Ortho Partners with THINK Surgical to Expand MOBIO Knee System in U.S. Market
•
b-ONE Ortho Corp., a developer of artificial joint replacements with operations in the U.S. and China, has entered into a partnership with U.S.-based THINK Surgical to advance the market for its MOBIO total knee joint system alongside THINK’s orthopedic surgical robots in the United States. The MOBIO system, known for…
-
CardioACC Initiates Regulatory Study for Groundbreaking 7.5F Intracardiac Ultrasound System
•
CardioACC, a Shenzhen-based company specializing in cardiovascular interventional imaging and treatment technologies, has launched a regulatory study for its 7.5F 2D intracardiac ultrasound imaging system (ICE), successfully enrolling dozens of patients. This ultrasound catheter model is smaller than any currently marketed ICE products globally, nearing the industry’s design limits. The…
-
Jiangsu Nhwa Secures Exclusive Rights to Teva’s Austedo in China with $30 Million Deal
•
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation agreement with Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), securing exclusive commercialization rights for Austedo (deutetrabenazine) in mainland China. Austedo, a vesicle monoamine transporter 2 (VMAT2) inhibitor, received its initial approval in the U.S. in 2017…
-
Guangdong Province Releases New Batch of Urgently Needed Drugs and Medical Devices for Greater Bay Area
•
The Medical Products Administration and Health Commission of Guangdong province have released the sixth batch of urgently needed imported drugs and medical devices for clinical use in the Guangdong-Hong Kong-Macao Greater Bay Area. This latest list includes two new drugs and ten medical devices, while also adding indications to one…
-
Tencent Hands Over Two Former CSIG Employees to Authorities on Embezzlement Allegations
•
Chinese internet conglomerate Tencent has announced via its anti-fraud department’s official channel that former employees Zhang Meng and Liu Yunting from the Cloud and Smart Industries Group (CSIG) have been handed over to public security authorities. The two are suspected of misusing their positions to embezzle company assets and to…
-
Sanofi’s Dupixent Receives FDA Priority Review for COPD Indication Extension
•
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, announced last week that the US Food and Drug Administration (FDA) has accepted for priority review an indication extension filing for its interleukin blocker Dupixent (dupilumab). The drug is proposed as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD),…
-
Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries
•
China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic firm Yabao Pharmaceutical Group Co., Ltd. (SHA: 600351) to distribute a generic version of Bayer (ETR: BAYN)’s Nexavar (sorafenib). Under this agreement, Kexing will serve as the exclusive agent for the tyrosine kinase inhibitor (TKI)…
